How to appeal a Cigna bone marrow transplant (allogeneic hsct) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for bone marrow transplant (allogeneic hsct)

Cited policy: Cigna Jakafi (Ruxolitinib) for Acute and Chronic GVHD

Steroid-refractory acute GVHD: failed 7-day course of methylprednisolone 2 mg/kg or equivalent per MAGIC consensus. Steroid-refractory or steroid-dependent cGVHD: failed prior systemic therapy per NIH consensus criteria. Adult and pediatric ≥12 yo. BMT-trained Rx. Reauth at 4-8 weeks with response documentation.

How Cigna denies bone marrow transplant (allogeneic hsct) — and how to counter it

Where Cigna pushes back: 1) Try mycophenolate / ECP / etanercept first; 2) Pediatric off-label; 3) Steroid-refractory criteria not met; 4) cGVHD severity below threshold.

Counter-arguments that hold up: REACH-2 (Zeiser NEJM 2020;382:1800-1810) — ruxolitinib vs BAT in steroid-refractory aGVHD, day-28 OR 0.62 (62% vs 39%). FDA May 24, 2019 — first FDA-approved drug for steroid-refractory aGVHD. REACH-3 (Zeiser NEJM 2021;385:228-238) — week 24 ORR 49.7% vs 25.6% in steroid-refractory cGVHD. FDA Sep 22, 2021 cGVHD approval. NCCN-endorsed; ASTCT/EBMT consensus 2022 list Jakafi as preferred 2L. Pediatric ≥12 yo per FDA label expansion. Steroid-refractory: no improvement after 5-7 days of high-dose steroids OR worsening within 3 days.

What Cigna typically denies for bone marrow transplant (allogeneic hsct)

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For bone marrow transplant (allogeneic hsct), expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the bone marrow transplant (allogeneic hsct) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Allo-HSCT (MAC)
• Allo-HSCT (RIC)
• Allo-HSCT (NMA)
• MRD allo-HSCT
• MUD allo-HSCT
• Haplo allo-HSCT

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.